Evaluation of Cisplatin Efficacy on HepG2 and E. coli Cells under Acidic Conditions

Document Type : Research Articles

Authors

1 Anatomical Sciences Research Center, Kashan University of Medical Sciences, Kashan, Iran.

2 Department of Microbiology, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

3 Faculty of Medicine, Shahed University of Medical Sciences, Tehran, Iran.

4 Food and Drug Laboratory Research Center and Food and Drug Reference Control Laboratories Center, Food and Drug Administration of Iran, MOH and ME, Tehran, Iran.

Abstract

Background: Cisplatin (Cispt) is a common anticancer drug for the treatment of several malignancies, including
hepatocarcinoma. However, this drug suffers from instability in aqueous solutions. The study aimed to evaluate cisplatin
efficacy on HepG2 and E. coli cells under an acidic condition. Methods: Acidic Cispt was prepared via incubation in
acidic condition (pH=2) for a month duration. The chemical structure of the acidic Cispt was evaluated by using Fourier
Transform Infrared Spectroscopy (FTIR) method. The cytotoxicity of the standard and acidic Cispt were then determined
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and minimum inhibitory concentration (MIC)
assays on HepG2 and E. coli cells, respectively. Results: After preparing of acidic Cispt, its chemical structure was
determined by FTIR method. In addition, cytotoxicity effects of Cispt in the standard and acidic forms were calculated
58 ± 2.9 and 65 ± 3.25 μM, respectively. MIC results also confirmed the results of MTT assay. MIC results for the
standard and acidic Cispt were estimated 9.5 ± 0.47 and 9.8 ± 0.49 μM, respectively. Conclusion: Preparing Cispt in
acidic condition not only did not degrade the drug, but also kept the potency of the drug approximately equal to parent
drug. Regarding the instability issues of Cispt, keeping Cispt in acidic condition could be a promising approach to
preserve its efficacy.

Keywords

Main Subjects

Asian Pacific Journal of Cancer Prevention
Volume 20, Issue 3
March 2019
Pages 723-726

Files

History

  • Receive Date: 03 February 2018
  • Revise Date: 08 August 2018
  • Accept Date: 21 December 2018

Share

How to cite

Statistics